Fig 2: Correlation of DC-SIGNR expression levels with the degree of cervical cancer differentiation and age. (A) The mean density of DC-SIGNR in patients with well differentiated cervical cancer compared with those exhibiting cervical cancer with low differentiation. (B) The mean density of DC-SIGNR in patients =50 years old compared with those <50 years old. Data are presented as the mean ± standard deviation. DC-SIGNR, dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related protein.

Fig 3: Analysis of DC-SIGNR gene expression in HCC and normal tissues using online data. (A-E) The expression level of DC-SIGNR mRNA was significantly lower in HCC in (A) Wurmbach Liver Statistics, (B) Chen Liver Statistics, (C) Roessler Liver Statistics, (D) Roessler Liver 2 Statistics and (E) Mas Liver Statistics datasets. The data were obtained from https://www.oncomine.org. DC-SIGNR, dendritic cell-specific intercellular adhesion molecule-grabbing non-integrin-related protein; HCC, hepatocellular carcinoma.

Fig 4: The ten-year survival rate of patients with HCC is associated with DC-SIGNR expression. Patients with low DC-SIGNR expression exhibited a lower ten-year survival rate compared with patients with high DC-SIGNR expression. DC-SIGNR, dendritic cell-specific intercellular adhesion molecule-grabbing non-integrin-related protein.

Fig 5: Kaplan-Meier analysis of the association between CLEC4M expression in HCC tumor tissues and the survival of patients with HCC. (A) Recurrence-free and (B) overall survival curves suggest that patients with moderate- or strong-positive CLEC4M staining exhibit higher recurrence rates (P=0.0001) and shorter overall survival times (P=0.0011). These patients (n=29) had significantly higher recurrence rates and shorter overall survival times than those with negative or weak expression (n=59). HCC, hepatocellular carcinoma; CLEC4M, C-type lectin domain family 4 member M; RFS, recurrence free survival; OS, overall survival.